Moyamoya Disease
Conditions
Interventions
Observation group 1 (Surgery with antiplatelet agent continued):NA
Observation group 2 (Surgery with antiplatelet agent stopped):NA
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
4 Years to 80 Years
Inclusion criteria
Inclusion criteria: ? The diagnosis of MMD was confirmed with digital subtraction angiography (DSA) and/or MR angiography (MRA) or CT angiography (CTA). The diagnostic criteria for definitive or probable MMD were based on the criteria of the Research Committee on Spontaneous Occlusion of the Circle of Willis (2012): (a) stenosis and/or occlusion of the terminal portion of the ICA and the proximal portion of the anterior cerebral artery (ACA) and/or middle cerebral artery (MCA), (b) abnormal vascular networks near the lesion, and (c) unilateral or bilateral involvement. ? Patients present clinically with cerebral ischemia, including Transient Ischemic Attack (TIA) and cerebral infarction. Surgical treatment for cerebral revascularization is proposed, with various surgical approaches including direct revascularization, indirect revascularization, and combined revascularization. ? Before admission, patients receive antiplatelet drug therapy, such as aspirin, clopidogrel, cilostazol, indobufen, etc. ? Patients demonstrate a comprehensive understanding of the research objectives, willingly participate, and provide informed consent by signing a consent form. ? Patients demonstrate a willingness to adhere to the research program's requirements for conducting follow-up assessments and evaluations.
Exclusion criteria
Exclusion criteria: ? Patients with a history of cerebral hemorrhage or hemorrhagic Moyamoya disease. ? Patients with Moyamoya syndrome due to other established causes, including atherosclerosis, autoimmune diseases (such as systemic lupus erythematosus, antiphospholipid antibody syndrome, Sjögren's syndrome, hyperthyroidism, tuberous sclerosis, Marfan syndrome, etc.), meningitis, brain tumors, Type 1 neurofibromatosis, radiation-induced brain diseases, etc. ? Pregnant women. ? Individuals with contraindications for antiplatelet drug use. ? Patients with coagulation disorders or a predisposition to bleeding. ? Patients with concurrent severe conditions such as malignancies, significant hepatic or renal dysfunction, congestive heart failure, etc.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Intracranial Hemorrhage;Favorable neurologic outcome;Bypass patency; | — |
Primary
| Measure | Time frame |
|---|---|
| New Ischemic stroke or TIA ; | — |
Countries
CHINA
Contacts
Public ContactKunpeng Chen
Beijing Hospital
Outcome results
None listed